Recruiting

Long COVID

Sponsor:

UCLA

Code:

NCT07770022

Conditions

Long Covid

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Accepted

Study Details

Brief summary:

The purpose of this study is to better understand the biological changes associated with Long COVID and to identify laboratory tests (biomarkers) that may help diagnose the condition and measure how it changes over time. Researchers will enroll people with Long COVID as well as people who have fully recovered after COVID-19 infection.

Participants will provide health information and biological samples, such as blood, saliva, stool, and, for some participants, tissue biopsies. These samples will be used to study the biological processes involved in Long COVID and to support the development of new diagnostic tests that may improve future research, clinical trials, and patient care.

Conditions

Long Covid

Study ID

NCT07770022

Start date

May 18, 2026

Status verified date

Aug, 2026

Completion date

May 15, 2031

Anticipated

Primary completion date

May 15, 2031

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Accepted

Inclusion Criteria:

  • Willing and able to provide written informed consent, and
  • Age >/= 18 years, and
  • Either:

History of a SARS-CoV-2 infection resulting in Long COVID symptoms, confirmed by the investigator, or

Exposure to SARS-CoV-2 without establishment of Long COVID.

  • Enrolled or willing to enroll and complete at least 1 visit in the UCSF Long-term Impact of Infection with Novel Coronavirus (LIINC).
  • Enrolled or willing to be referred for a gut biopsy procedure under related IRB-approved protocols.

Exclusion Criteria:

  • Self-reported or documented chronic anemia with hemoglobin < 9 g/dL. Anemia during a preceding acute illness will not be exclusionary.
  • Serious medical or psychiatric illness that, in the opinion of the site investigator, would interfere with the ability to adhere to study requirements or to give informed consent.
  • Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.

Study Design

Enrollment

150 participants

Anticipated

Interventions and Outcome Measures

Arms

Long COVID

People experiencing Long COVID symptoms

Recovered

People who have fully recovered from their COVID infection(s)

Primary outcome measure

  • Participant age [ Time Frame: Baseline visit ]
  • Participant sex [ Time Frame: Baseline visit ]
  • Participant race/ethnicity [ Time Frame: Baseline visit ]
  • Proportion of participants previously hospitalized [ Time Frame: Baseline visit ]
  • Colonoscopy Completed [ Time Frame: Baseline visit ]

Central Contacts and Locations

Central contacts

VIPER Study UCSF

(415) 502-2449VIPERStudy@ucsf.edu

Lynn Ngo, MPH

(415) 322-8432Lynn.Ngo@ucsf.edu

Locations

Zuckerberg San Francisco General Hospital

Recruiting

San Francisco, California, United States, 94110

Contacts

Lynn Ngo, MPH

(415) 322-8432Lynn.Ngo@ucsf.edu

Principal Investigator:

Michael Peluso

More Information

Sponsor

University of California, San Francisco

Last update posted

Aug 18, 2026

Last verified

Aug, 2026

Keywords

  • Long COVID

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by University of California, San Francisco on 2026-08-18.